Engflag

Gastrosedol Plus

Quick links to important sections

Gastrosedol Plus

Gastrosedol Plus_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrosedol Plus

Property Description
Active Ingredients Ranitidine and Domperidone
Form Oral Coated Tablet
Pharmacological Class H₂-Receptor Antagonist & Prokinetic Agent
Origin Synthetic Fixed-Dose Combination
General Purpose Managing acid secretion and digestive motility simultaneously

Gastrosedol Plus is a specific, synthetic fixed-dose combination product designed for oral administration as a single coated tablet. This structure delivers two distinct active ingredients simultaneously, distinguishing it from single-component drugs. As a combination, it is structurally intended to provide a coordinated therapeutic action within the upper gastrointestinal tract, a strategy utilized for addressing multifaceted digestive discomfort.

Active Ingredients and Pharmacological Class of the Combination

The key components are Ranitidine (typically present as Ranitidine Hydrochloride) and Domperidone. Ranitidine is categorized as a Histamine H₂-receptor antagonist, a class of antiulcer agents that work to suppress the production of stomach acid. Domperidone is classified as a Prokinetic agent and a dopamine antagonist, which grants it antiemetic agent properties by primarily helping regulate the movement of the digestive system.

The intentional pairing of these two substances defines the drug’s unique identity, a formulation frequently utilized in the Argentine market. This dual composition ensures the medication can exert effects within two major pharmacological groups, offering a combined action that is not achievable with a single-agent drug.

What is the General Therapeutic Purpose of Combining Ranitidine and Domperidone?

The general therapeutic purpose of Gastrosedol Plus is to provide integrated management of upper gastrointestinal discomfort by targeting both acid secretion and physical motility. Ranitidine functions by decreasing the amount of acid the stomach produces, while Domperidone works to enhance gastric emptying and the movement of contents through the upper digestive tract. The combination of an H₂-blocker and a prokinetic agent is intended for managing conditions like functional dyspepsia.

The combination's benefit lies in its ability to address both the irritation caused by acid and the feeling of fullness or bloating caused by slow digestive movement. This coordinated approach is designed for normalizing the function of the upper digestive tract more comprehensively than either agent could achieve alone.

What side effects are possible with Gastrosedol Plus?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and high-level safety information for the fixed-dose combination of Ranitidine and Domperidone, based strictly on government regulatory documents.

Adverse Reaction Classification

The medicine's safety profile is categorized by regulatory bodies based on the affected System-Organ-Class (SOC) and the frequency of occurrence. Common adverse reactions, as documented in regulatory sources, include headache, fatigue or malaise, and dry mouth. Uncommon events often involve gastrointestinal disturbances such as diarrhea or constipation, and skin reactions like rash.

Serious Adverse Reactions and Safety Constraints

The regulatory label identifies specific rare but clinically significant Serious Adverse Reactions (SARs). These include serious ventricular arrhythmias and QT prolongation associated with the Domperidone component, as well as anaphylactic shock, hepatitis, and blood disorders linked to Ranitidine. The profile is structured by safety constraints that restrict use in certain conditions.

Use is officially contraindicated in patients with pre-existing cardiac conductivity abnormalities, severe hepatic impairment, or conditions like gastrointestinal hemorrhage or prolactinoma.

Population and Duration Patterns

The safety profile includes specific considerations for certain groups. Older adults may have an increased risk of central nervous system effects (Ranitidine) and heightened cardiovascular risk (Domperidone). The official documents note that effects such as hyperprolactinemia (e.g., galactorrhea) are associated with long-term exposure, while others like extrapyramidal reactions may be observed early in treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Gastrosedol Plus

This section describes only the officially documented overdose manifestations and mandated emergency actions for the active components, Ranitidine and Domperidone, as stated in government regulatory sources.

Overdose scope

Documented overdose presentations: Excessive exposure is associated with central nervous system (CNS) manifestations, including somnolence, agitation, disorientation, convulsions, and extrapyramidal reactions (involuntary movements). Additionally, hypotension (low blood pressure) and changes in heart rate (slow or fast) have been documented.

Physiological systems affected (as stated in label): Primary systems officially noted are the Cardiovascular system (risk of arrhythmia, low blood pressure) and the Central Nervous System (CNS disturbances and neuromuscular effects).

Dose-related or exposure-related factors (if applicable): Overdose exposure may increase the risk of serious adverse events, particularly the potential for QT-interval prolongation associated with Domperidone, which can lead to severe cardiac outcomes.

Population-specific overdose notes (if applicable): Official labeling generally indicates that the risk of severe cardiac effects with Domperidone is higher in older adults and those taking doses higher than recommended.

Emergency-response statements (as written in official documents): Immediate medical attention must be sought for any suspected overdose. Due to the severe cardiac risk, hospital monitoring and continuous electrocardiogram (ECG) surveillance are explicitly required.

When immediate medical help is required (label-derived phrasing only): Immediate medical help is required for any suspected or confirmed overdose because of the documented potential for life-threatening irregular heartbeats and severe neurological depression.

Overdose classifications (high-level)

Severity classification (as defined in official documents): The potential for severe and life-threatening outcomes, particularly related to the heart rhythm (Torsades de Pointes), is documented.

Regulatory basis (EMA / FDA / etc.): Information is drawn from the official regulatory documents of health authorities such as the EMA, FDA, and MHRA for the active components.

Overdose-context constraints (as defined in official documents): Management is symptomatic and supportive, as regulatory documents state that no specific antidote is known for this combination.

Resulting overdose structure

Official overdose statements:

  • Overdose is explicitly linked to the risk of QT-interval prolongation and severe ventricular arrhythmias.
  • Manifestations include agitation, convulsions, disorientation, extrapyramidal reactions, and hypotension.
  • Immediate medical attention must be sought, and continuous ECG surveillance is a mandatory part of hospital management.
  • No specific antidote is known; treatment is officially classified as symptomatic and supportive.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by highlighting the serious cardiac and CNS risks associated with the components. This profile mandates that individuals seek immediate medical attention and undergo specialized hospital monitoring and supportive care, given the potential severity of documented outcomes and the lack of a specific antidote.

Therapeutic Uses of Gastrosedol Plus

Main Uses of Gastrosedol Plus

Gastrosedol Plus is a combination medication designed to address several common gastrointestinal issues. Its primary function is to manage symptoms related to excessive gastric acid and the presence of gas within the digestive tract. It is typically used for the following conditions:

  • Acid Indigestion and Heartburn: It helps neutralize existing stomach acid, providing relief from the burning sensation in the chest or throat often associated with acid reflux.
  • Gastritis: The medication is used to manage the symptoms of inflammation of the stomach lining, which can cause discomfort, bloating, and nausea.
  • Peptic Ulcers: It may be used as an adjunct treatment to relieve the pain associated with gastric or duodenal ulcers by reducing the acidity of the stomach environment.
  • Flatulence and Gas Pressure: The inclusion of an anti-foaming agent helps to break down gas bubbles in the gut, easing the symptoms of bloating, pressure, and fullness.

Therapeutic Benefits

The benefits of Gastrosedol Plus stem from its multi-action approach to digestive discomfort. By combining acid-neutralizing agents with gas-relieving components, the medication offers several clinical advantages:

Neutralization of Gastric Acid

Gastrosedol Plus works quickly to raise the pH level of the stomach contents. This neutralization process protects the esophageal and gastric mucosa from the irritating effects of hydrochloric acid, which is particularly beneficial for individuals experiencing frequent heartburn.

Reduction of Gastrointestinal Gas

Accumulated gas can cause significant abdominal stretching and pain. One of the key benefits of this formulation is its ability to change the surface tension of gas bubbles, allowing them to be eliminated more easily. This reduces the physical discomfort and visible bloating often found in various functional digestive disorders.

Symptomatic Relief and Mucosal Protection

By maintaining a less acidic environment, the medication supports the natural healing process of the stomach lining. It provides a temporary protective barrier and reduces the aggressive factors that contribute to epigastric pain and discomfort during digestion.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gastrosedol Plus

Regulatory documents strictly define the patient populations eligible for Gastrosedol Plus (Ranitidine + Domperidone). The medicine is generally allowed for adults and for adolescents 12 years of age and older weighing 35 kg or more. Use is not recommended for children under 12, as safety and effectiveness have not been established.

Absolute Contraindications

Use is contraindicated (must not be used) in patients with specific high-risk conditions, primarily due to the Domperidone component's cardiac risks and Ranitidine's metabolic restrictions. These include:

  • Patients with moderate or severe hepatic impairment or a history of acute porphyria.
  • Individuals with known prolongation of cardiac conduction intervals (QTc), underlying cardiac diseases like congestive heart failure, or significant electrolyte disturbances.
  • Patients with conditions where increased gastrointestinal motility is harmful (e.g., gastrointestinal haemorrhage, mechanical obstruction, or perforation).

Restrictions and Conditional Use

  • Severe Renal Impairment requires reduced dosing frequency.
  • Older adults require caution and monitoring due to increased cardiac risk.
  • During pregnancy or lactation, use is conditional, typically allowed only if the anticipated therapeutic benefit outweighs the potential risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions for the active components, Ranitidine and Domperidone, based on official regulatory prescribing information.

Formally Contraindicated Combinations

The co-administration of the Domperidone component with certain medicinal products is formally contraindicated due to the risk of serious ventricular arrhythmias. This restriction applies to strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and drugs that prolong the QTc interval (e.g., certain anti-arrhythmics, antipsychotics like pimozide).

Pharmacokinetic Interaction Constraints

Interaction Type Interacting Substance Examples Implication in Regulatory Documents
Gastric pH Dependent Atazanavir, Oral Ketoconazole Ranitidine may reduce absorption and exposure of these drugs.
CYP3A4 Metabolism Moderate Inhibitors (e.g., Diltiazem) Increase in Domperidone plasma concentration; use requires caution.
Renal Transport Procainamide High-dose Ranitidine may reduce clearance, increasing co-administered drug levels.

Procedural and Population-Specific Notes

Co-administration with Antacids or Antisecretory Agents requires timing separation to avoid reduced Domperidone bioavailability. Furthermore, regulatory documents note that the risk of interaction-related arrhythmias is higher in elderly patients and those with severe renal impairment.

Mechanism of Action

Modulating Gastric Acid Production Through H2-Receptor Blockade

This core mechanistic domain involves a component that selectively targets histamine H2-receptors on gastric parietal cells, acting as an antagonist. By occupying these receptor sites, the component interrupts a primary signaling pathway for stimulating the proton pump, which results in a substantial reduction in the volume and concentration of secreted stomach acid.

Enhancing Gastrointestinal Movement Via D2-Receptor Antagonism

The second mechanistic domain focuses on promoting motility through the peripheral D2-dopamine receptor in the upper digestive tract. Antagonism at this receptor increases the release of acetylcholine, a neurotransmitter that enhances the tone and coordination of smooth muscle contractions. This cascade improves the forward movement of contents and increases the resting tone of the muscular barrier at the lower esophagus.

The Coupled Physiological Modulation

Gastrosedol Plus operates across two distinct but complementary mechanisms: one to create an environment with reduced acidity by dampening acid secretion, and the other to increase the transit rate and the resistance by regulating muscle activity. The drug’s observed physiological impact stems from the simultaneous modulation achieved by these two actions within the gastrointestinal system.

Dosage and Administration Information

Official Administration Guidelines

The following guidelines for Gastrosedol Plus, a fixed-dose combination tablet of Ranitidine 150 mg and Domperidone 10 mg, describe its use as specified in official documentation.

Feature Administration Protocol
Route & Form Oral ingestion of the film-coated tablet.
Dosing Schedule Typically administered as one tablet per dose, once or twice daily. Dosing frequency and duration are determined by the specific treatment plan.
Timing & Intake The tablet should be taken before a meal with a glass of water. It must be swallowed whole and is not to be crushed, chewed, or broken, as this could compromise the intended drug release.
Dosing Interval When taken more than once per day, a minimum interval of at least 8 hours should be maintained between doses of the Domperidone component to align with established frequency guidelines.
Duration of Use Treatment is prescribed for a defined, short-term course.
Renal Adjustment Dosage adjustment is necessary for patients with impaired renal function. For the Ranitidine component, the recommended oral dose is often reduced to 150 mg every 24 hours in patients with a creatinine clearance less than 50 mL/min.

Procedural Structure

The official use protocol is structured around three key procedural steps:

  • Swallow the tablet whole with water (Do not alter the physical form).
  • Administer the dose before a meal (Adhere to time-relationship constraints).
  • Maintain the prescribed short-term course and time interval between doses (Respect frequency and duration limits).

The administration guidelines establish a standardized protocol centered on correct timing and method of intake to ensure the proper delivery of both active components to the gastrointestinal tract. Adherence to these instructions, including the limits on daily dose and necessary adjustments for altered renal function, defines the standardized use of the medication.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research on Study Endpoints

Research has evaluated the relationship between this medication and study endpoints related to pain and inflammation, with some clinical trials reporting an observed change in both measurements compared to placebo.

  • One study assessed the relationship between the drug and biochemical markers, focusing on compounds associated with inflammatory pathways.
  • Pharmacokinetic analysis examined the drug's elimination, finding that the half-life in plasma was approximately 2 hours in healthy volunteers. This parameter helps researchers understand how quickly the drug concentration is reduced in the body.

Study Design: Dosage and Administration

Clinical studies investigated various dosing schedules to characterize the relationship between dose and response.

  • Research protocols evaluated doses ranging up to 400mg in divided administrations.
  • Doses higher than 400mg were explored in a limited number of trials. Evidence regarding the long-term observed effects of higher doses remains limited.

Potential Observed Effects

The adverse event profile was a primary endpoint in many trials. Research has investigated the risk profile, particularly focusing on gastrointestinal (GI) and cardiovascular events.

  • Studies explored the observed incidence of gastrointestinal (GI) side effects when this drug was administered in combination with a proton pump inhibitor (PPI).
  • GI side effects were the most frequently reported adverse events in the documented placebo-controlled trials, including mild nausea or dyspepsia.

Research has also investigated whether this medication was associated with increased risk of cardiovascular events in some patient groups. Specifically, clinical trials examined rates of myocardial infarction and stroke compared to a placebo group in certain cohorts.

Summary

Overall, the evidence provides initial findings from the study populations involved in the research. Further research is needed to fully characterize the long-term observed effects and comparative findings of this medication against established treatments.

Key Studies & References

  1. Ibuprofen Product Information (TGA)
  2. Ibuprofen - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Gastrosedol Plus (FAQ)

Q: Are there any common food or drink restrictions when taking Gastrosedol Plus?

A: Official administration documents describe that the medicine's protocol involves taking it before a meal to ensure proper timing of its effects. However, absorption of the ranitidine component is not significantly impaired by food. Separately, official product information indicates that the combination with grapefruit juice should be avoided due to specific potential interactions.

Q: Does taking Gastrosedol Plus mean I need to avoid any specific over-the-counter medicines?

A: Yes, official regulatory warnings state that the domperidone component is formally contraindicated with certain medicines that prolong the heart's electrical rhythm, known as the QTc interval. Separation in timing is also needed if the patient is taking antacids or other acid-reducing agents. The official protocol states that a discussion with a healthcare professional regarding all concurrent medications is necessary.

Q: What type of stomach issues does Gastrosedol Plus not treat?

A: The medicine’s general purpose is defined as managing acid secretion and digestive motility. However, official information states it is not indicated for conditions where increasing gastrointestinal movement could be harmful, such as cases of gastrointestinal hemorrhage (bleeding), mechanical obstruction, or perforation of the gut wall. The medicine is intended to address only acid- and motility-related abdominal issues.

Q: Does Gastrosedol Plus interact with anti-depressant medications?

A: The domperidone component carries a regulatory warning regarding medicines that affect the heart's electrical activity. This means that certain types of anti-depressants and anti-psychotics that are known to prolong the QTc interval (the time it takes for the heart to recharge between beats) may be formally contraindicated. The official product information indicates that consulting a healthcare professional is necessary when discussing concurrent medications.

Q: How quickly does Gastrosedol Plus usually start working?

A: Studies on the Ranitidine component indicate that plasma concentrations necessary to inhibit stomach acid secretion are generally reached within two to three hours after a dose. The regulatory text indicates that these acid-suppressing effects may be maintained for a duration of up to 12 hours following a single dose. Official information does not provide an exact time for the onset of the motility component’s effect.

Q: How long does the effect of Gastrosedol Plus typically last?

A: Research indicates that the ranitidine component, following a single dose, is associated with a suppression of gastric acid secretion lasting for at least twelve hours. This effect helps to reduce the volume and concentration of secreted stomach acid over that time period. The duration of the combined therapeutic effect will vary depending on the patient’s clinical status.

Q: Is it possible for Gastrosedol Plus to cause weight gain?

A: Official reports for the Domperidone component have listed weight gain as a potential effect, which has been documented in association with the drug. This information is noted in regulatory safety summaries and adverse event profiles for the active ingredient.

Q: Can Gastrosedol Plus affect my sleep?

A: The regulatory documents for the active ingredients note that central nervous system effects are possible. The domperidone component has been associated with reports of insomnia (difficulty sleeping) and other central nervous system effects in some patients, particularly upon discontinuation. Fatigue is also reported as a common side effect in regulatory documentation.

Q: Is it normal to feel slightly dizzy after taking Gastrosedol Plus?

A: Official documents for the domperidone component describe dizziness as a possible side effect. Patients are also warned that feeling dizzy can be a symptom of a more serious, although rare, cardiac event, which is why pre-existing cardiac conditions are often a contraindication for use.

Q: Is there a risk of dependency or withdrawal with Gastrosedol Plus?

A: Official reports state that the abrupt discontinuation of the domperidone component, especially after long-term or high-dose use, has been associated with withdrawal symptoms. These effects may include feelings of anxiety, insomnia, or confusion. Regulatory information notes that tapering (a gradual reduction of the dose) is the recommended procedure for discontinuation.

Q: Are there any known interactions between Gastrosedol Plus and common vitamins or supplements?

A: Official guidance indicates that patients should inform their healthcare provider about all concomitant medications, including herbal medications, vitamins, or supplements. This is because official documents do not contain comprehensive information confirming the safety of combining this drug with all complementary medicines.

Q: Is it safe to drive after taking Gastrosedol Plus?

A: The official safety profiles indicate that the medicine may cause dizziness and other central nervous system effects. Official patient information notes that due to the potential for altered awareness, caution is indicated when driving or operating machinery.

Q: Are there known interactions between Gastrosedol Plus and herbal remedies?

A: Official regulatory advice includes a statement regarding the importance of disclosing all concomitant medications, including any herbal remedies they are using. This guidance is provided because official documents do not contain comprehensive information confirming the safety of combining this drug with all complementary medicines.

Q: Does Gastrosedol Plus contain lactose?

A: While the specific excipient list for this combination product is generally not included in high-level patient summaries, regulatory documents for many Ranitidine tablets often list lactose as an inactive ingredient. This indicates that it may be present in the final product formulation.

How should Gastrosedol Plus be stored and disposed of?

How to Store and Dispose of Gastrosedol Plus

The storage and disposal instructions for Gastrosedol Plus are strictly defined in the official regulatory labeling to ensure product stability and public safety.

Storage Condition Official Requirement
Temperature Store at a temperature not exceeding 30°C (or below 25°C), as specified on the label.
Protection Must be stored in a cool, dry, and dark place and protected from light and moisture.
Container Keep the medicine in its original container and keep tightly closed.

The product must be kept out of the sight and reach of children at all times. Regarding disposal, unused or expired Gastrosedol Plus must be disposed of according to local requirements and must not be flushed or discarded with household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Gastrosedol Plus found in:

A-Z Index: